⠀
📊 𝐑𝐞𝐬𝐮𝐥𝐭𝐬
• Revenue: $150.7M (+1% YoY)
• GAAP EPS: -$0.15 vs. -$0.22 YoY
• Net Loss: -$19.4M vs. -$27.5M YoY
• Operating Loss: -$16.1M vs. -$32.2M YoY
• Gross Margin: 75% vs. 67% YoY (+800 bps)
• Operating Expenses: $129.0M (-3% YoY)
• Cash & Marketable Securities: $575.7M
⠀
🎯 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 (𝐅𝐘𝟐𝟎𝟐𝟔, 𝐑𝐚𝐢𝐬𝐞𝐝)
• Revenue: $625M–$635M (prior $610M–$630M)
• Revenue Growth: +4% to +6% YoY, excluding non-recurring settlement-related revenue
⠀
📌 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
• Gross margin expanded 800 bps, primarily from lower inventory write-downs and favorable product mix
• Operating loss narrowed by approximately 50% YoY
• Began global commercial shipments of Atera, reporting strong initial customer demand
• Introduced Sentira, a cloud-based biological data analysis platform
• Sentira uses NVIDIA accelerated computing for spatial data processing and Anthropic's Claude for agentic AI analysis of single-cell data
• Nine-month revenue declined 5% to $452.5M
• Nine-month net loss widened to $50.8M from $27.3M YoY
• FY26 revenue guidance midpoint increased $10M to $630M
• Strong liquidity provides flexibility to support new product commercialization
⠀
💬 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐞𝐧𝐭𝐚𝐫𝐲
“As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.” - CEO Serge Saxonov
